M&A / Property
Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease
AI cardiac imaging startup scaling niche partnerships while navigating a critical $55k cash balance and negative working capital.
Executive Summary
- Ventripoint Diagnostics announced a strategic collaboration with the Ollie Hinkle Heart Foundation (OHHF) to expand access to its AI-powered VMS+ cardiac imaging platform for pediatric and congenital heart disease patients.
- OHHF will provide initial financial support to deploy two VMS+ systems within its healthcare partner network.
- The partnership integrates OHHF’s "Take Heart Collective Impact Model" to align families, clinicians, and innovators, aiming to reduce barriers to advanced cardiac imaging and support patient monitoring.
- The VMS+ platform uses AI to provide MRI-level volumetric measurements from standard echocardiograms and holds regulatory approvals in the U.S., Europe, and Canada.
Material Impact
- The deployment of two systems is operationally incremental and does not materially impact revenue or cash flow given the company's FY2025 revenue of $179,928 CAD.
- The partnership serves as a strategic validation for the company's focus on underserved pediatric/congenital markets, aligning with its broader commercialization and hub-and-spoke distribution strategy.
- No new capital is raised, and the financial support is limited to initial deployment costs. The news does not alter the company's immediate liquidity constraints or debt obligations.
VPT · Price
Company Overview
- Ventripoint Diagnostics Ltd. is a medical technology company commercializing the VMS+™ platform, an AI-driven software that converts standard 2D echocardiograms into highly accurate 3D volumetric heart models.
- The technology aims to provide MRI-level diagnostic accuracy at the point of care, reducing reliance on costly and time-consuming cardiac MRIs.
- The company is transitioning from a product development phase to a commercial execution phase, utilizing a Device-as-a-Service (DaaS) subscription model to shorten sales cycles and generate recurring revenue.
- Target markets include congenital heart disease, heart failure, pulmonary hypertension, and cardiotoxicity monitoring, with a focus on underserved, remote, and Indigenous communities through hub-and-spoke deployment models.
More from VentriPoint Diagnostics Ltd.
Jun 16, 2026 · 09:11